The effects of edaravone in ketamine-induced model of mania in rats

• Autorzy: Arslan F.C. , Tiryaki A. , Yildirim M. , Ozkorumak E. , Alver A. , Altun I.K. , Ince I. , Gedikli O.
• Języki publikacji: EN

Abstrakty

EN

Bipolar disorder is a chronic disease characterized by recurring episodes of mania and depression that can lead to disability. This study investigates the protective effects of edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a drug with well-known antioxidant properties, in a model of mania induced by ketamine in rats. Locomotor activity was assessed in the open-field test. Superoxide dismutase (SOD), catalase (CAT) and thiobarbituric acid reactive substances (TBARS) levels were measured in order to evaluate oxidative damage in the rat hippocampus and prefrontal cortex. Increased locomotor activity (hyperlocomotion) was observed at the open-field test with ketamine treatment (25 mg/kg, i.p., 8 days). Edaravone (18 mg/kg) treatment did not prevent hyperlocomotion in the mania model induced with ketamine in rats, but lithium chloride (47.5 mg/kg, i.p., positive control) did prevent hyperlocomotion. Edaravone and lithium chloride treatments were found to reduce the increase in SOD and CAT activity following ketamine administration in a non-significant manner but caused no change in TBARS levels.

• Wydawca: -
• Czasopismo: Acta Neurobiologiae Experimentalis
• Rocznik: 2016
• Tom: 76
• Numer: 3
• Opis fizyczny: p.192-198,fig.,ref.

Twórcy

autor

Arslan F.C.

• Department of Psychiatry, School of Medicine, Karadeniz Technical University, Trabzon, Turkey

autor

Tiryaki A.

• Department of Psychiatry, School of Medicine, Karadeniz Technical University, Trabzon, Turkey

autor

Yildirim M.

• Department of Medical Physiology, Faculty of Medicine, Health Sciences University, Istanbul, Turkey

autor

Ozkorumak E.

• Department of Psychiatry, School of Medicine, Karadeniz Technical University, Trabzon, Turkey

autor

Alver A.

• Department of Biochemistry, School of Medicine, Karadeniz Technical University, Trabzon, Turkey

autor

Altun I.K.

• Department of Psychiatry, School of Medicine, Karadeniz Technical University, Trabzon, Turkey

autor

Ince I.

• Department of Biochemistry, School of Medicine, Karadeniz Technical University, Trabzon, Turkey

autor

Gedikli O.

• Department of Physiology, School of Medicine, Karadeniz Technical University, Trabzon, Turkey

Bibliografia

• Alhaider IA (2013) Effects of edaravone on scopolamine induced-dementia in experimental rats. Int J Pharmacol 9(4): 271–276.
• Amanda VS, Samira SV, Morgana M, Felipe D, João Q (2010) Role of oxidative stress in the pathophysiology of bipolar disorder. Neurochem Res 5: 1295–1301.
• Andreazza AC, Kauer-Sant’anna M, Frey BN, Bond DJ, Kapczinski F, Young  LT, Yatham LN (2008) Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 111: 135–144.
• Berk M, Dean O, Cotton SM, Gama CS, Kapczinski F, Fernandes BS, Kohlmann K, Jeavons S, Hewitt K, Allwang C, Cobb H, Bush AI, Schapkaitz I, Dodd S, Malhi GS (2011) The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord 135: 389–394.
• Brocardo PS, Budni J, Pavesi E, Franco JL, Uliano-Silva M, Trevisan R, Terenzi  MG, Dafre AL, Rodrigues A (2010) Folic acid administration prevents ouabain-induced hyperlocomotion and alterations in oxidative stress markers in the rat brain. Bipolar Disord 12: 414–424.
• Brüning AC, Prigol M, Luchese C, Pinton S, Nogueira CW (2012) Diphenyl diselenide ameliorates behaioral and oxidative parameters in an animal model of mania induced by ouabain. Prog Neuropsychopharmacol Biol Psychiatry 38: 168–174.
• Gandhi S, Abramov AY (2012) Mechanism of oxidative stres in neurodegeneration. Oxid Med Cell Longev 2012: 428010, http:// dx.doi. org/10.1155/2012/428010.
• Gazal M, Valente MR, Acosta BA,Acosta BA, Kaufmann FN, Braganhol E, Lencina CL, Stefanello FM, Ghisleni G, Kaster MP (2014) Neuroprotective and antioxidant effects of curcumin in a ketamine-induced model of mania in rats. Eur J Pharmacol 724: 132–139.
• Ghedim FV, Fraga DB, Deroza PF, Oliveira MB (2012) Evaluation of behavioral and neurochemical changes induced by ketamine in rats: implications as an animal model of mania. J Psychiatr Res 46: 1569–1575.
• Goth L (1991) A simple method for determination of serum catalase activity and revision of reference range. Clin Chim Acta 196(2–3): 143–152.
• Gould TJ, Keith RA, Bhat RV (2001) Differential sensitivity to lithium’s reversal of amphetamine-induced open-field activity in two inbred strains of mice. Behav Brain Res 118: 95–105.
• Jornada LK, Valvassori SS, Steckert AV, Moretti M, Mina F, Ferreira CL, Arent  CO, Dal-Pizzol F, Quevedo J (2011) Lithium and valproate modulate antioxidant enzymes and prevent ouabain-induced oxidative damage in an animal model of mania. J Psychiatr Res 45: 162–168.
• Kato T, Kubota M, Kasahara T (2007) Animal models of bipolar disorder. Neurosci Biobehav Rev 31: 832–842.
• Kikuchi K, Takeshige N, Miura N, Morimoto Y, Ito T, Tancharoen S, Miyata K, Kikuchi C, Iida N, Uchikado H, Miyagi N, Shiomi N, Kuramoto T, Maruyama  I, Morioka M, Kawahara KI (2012) Beyond free radical scavenging: beneficial effects of edaravone (Radicut) in various diseases. Exp Ther Med 3(1): 3–8.
• Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N (2002) Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 20: 171–175.
• Machado-Vieira R, Andreazza AC, Viale CL, Zanatto V, Cereser V Jr, Vargas R, Kapczinski F, Portela LV, Souza DO, Salvador M, Gentil V (2007) Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 421: 33–36.
• Mahadik SP, Evans D, Lal H (2001) Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 25(3): 463–493.
• Marcondes FK, Bianchı FJ, Tanno AP (2002) Determination of the estrous cycle phases of rats: some helpful considerations. Braz J Biol 62(4A): 609–614.
• Mihara M, Uchiyama M (1978) Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 86: 271.
• Otomo E, Tohgi H, Kogure K, Hirai S, Takakura K, Terashi A, Gotoh F, Maruyama S, Tazaki Y, Shinohara Y, Ito E, Sawada T, Yamaguchi T, Kikuchi  H, Kobayashi S, Fujishima M, Nakashima M (2003) Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction: Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 15: 222–229.
• Ozcan ME, Guleç M, Ozerol E, Polat R, Akyol O (2004) Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 19: 89–95.
• Price LH, Heninger GR (1994) Lithium in the treatment of mood disorders. N Engl J Med 331: 591–598.
• Riegel RE, Valvassori SS, Elias G, Réus GZ, Steckert AV, de Souza B, Petronilho  F, Gavioli EC, Dal-Pizzol F, Quevedo J (2009) Animal model of mania induced by ouabain: evidence of oxidative stress in submitochondrial particles of the rat brain. Neurochem Int 55: 491–495.
• Selek S, Savas HA, GergerlioğluHS, Bulbul F, Uz E, Yumru M (2008) The Course Of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J Affect Disord 107: 89–94.
• Souza LC, Wilhelm EA, Bortolatto CF, Nogueria CW, Boeira SP, JesseCR (2014) The protective effect of melatonin against brain oxidative stress and hyperlocomotion in a rat of mania induced by oubain. Behav Brain Res 271: 316–324.
• Sun Y, Oberlay LW, Li Y (1988) A simple method for clinical assay of superoxide dismutase. Clin Chem 34: 487–500.
• Ter-Minassian A (2006) Cerebral metabolism, brain injury (in French). Ann Fr Anesth Reanim 7: 714–721.
• Wang YC, Wang EN, Wang CC, Huang CL, Huang AC (2013) Effects of lithium and carbamazepine on spatial learning and depressive behavior in a rat model of bipolar disorder induced by ouabain. Pharmacol Biochem Behav 205: 118–127.
• Yoshida H, Yanai H, Namiki Y, Fukatsu-Sasaki K, Furutani N, Tada N (2006) Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury. CNS Drug Rev 12(1): 9–20.
• Zhou S, Yu G, Chi L, Zhu J, Zhang W, Zhang L (2013) Neuroprotective effects of edaravone on cognitive deficit, oxidative stress and tau hyperphosphorylation induced by intracerebroventricular streptozotocin in rats. Neurotoxicology 38: 136–145.
• Zugno AI, Chipindo HL, Volpato AM, Budni J, Steckert AV, De Oliveria MB, Heylmann AS, Da Rosa Silveria F, Mastella GA, Maravai SG, Wessler PG, Binatti AR, Panizzutti B, Schuck PF, Quevedo J, Gama S (2013) Omega-3 prevents behaviour response and brain oxidative damage in the ketamine model of schizophrenia. Neuroscience 259: 223–231.